We are a group of ordinary individuals
doing extraordinary things with a strong conviction.
Asher is a Ph.D. candidate in physics at Northeastern University. He has previously worked at the Center for Interdisciplinary Research on Complex Systems at Northeastern University to visualize the robust yet fragile nature of the signaling networks. He has also worked at Channing Division of Network Medicine, Department of Medicine at Brigham and Women’s Hospital on a variety of collaborative projects on complex systems including the integration of multi-omics networks, disease-disease relationship and link prediction approaches. Asher is developing some versatile approaches via graph mining and neural networks to extract the latent features of the biological data.
Albert-László Barabási, PhD
Dr. Albert-Laszlo is The Robert Gray Dodge Professor of Network Science and a Distinguished University Professor at Northeastern University. There, he directs the Center for Complex Network Research and holds appointments in the Department of Medicine at Harvard Medical School and Brigham and Women Hospital. He is also a member of the Center for Cancer Systems Biology at Dana Farber Cancer Institute. He received his MSc degree in Theoretical Physics at the Eötvös University and was awarded a Ph.D. three years later at Boston University.
Accolades: Dr. Albert-Laszlo is the author of NPR-acclaimed “Bursts” and many other influential works, including his most recent: “Network Science.” His work led to the discovery of scale-free networks in 1999, and proposed the Barabási-Albert model to explain their widespread emergence phenomenon in fields ranging from medicine to the Internet
Over the last decade, Adam has worked from bench to bedside to execute innovative clinical trial solutions throughout neurology and oncology. Having worked in both academic medical centers (University of Kentucky, Beth Israel Deaconess Medical Center) and diagnostics, Adam joined Scipher from Foundation Medicine where he led the establishment of the Clinical Operations team from the ground, installing the operational standards from which the academic research program was built. An alumnus of St. Lawrence University and Boston University’s School of Medicine, Adam has earned degrees in behavioral neuroscience, and medical sciences.
Chief Commercial Officer
During her 20+ year career in the pharmaceutical industry in business development and global sales and marketing leadership roles at UCB and Pfizer, Sophie also successfully built commercial operations for technology-based, personalized medicine growth companies such as Variagenics and CogState. Sophie received her MSc degree in Chemical and Biotechnology Engineering from University of Brussels (Belgium), Medicinal Chemistry from University of Lille (France), and her certificate of Business Excellence from the Columbia Management Institute in NY.
Dina Ghiassian, PhD
Director of Systems Biology and Network Medicine
Working with Dr. Albert-Laszlo Barabasi and Dr. Joseph Loscalzo, Dina has led the work of applying network science in medicine and developed a suite of tools that are used by scientists and engineers across the world to improve the understanding of complex diseases and patient drug response.
Dina continues to explore the frontier of what predictive models can achieve in medicine using her and Scipher’s unique multidiscipline approach including machine learning, graph theory, bioinformatics, and medicine. She received her PhD in Physics from Northeastern University’s Center for Complex Network Research.
Director of Clinical Development Program, Ulcerative Colitis
Anna joined Scipher Medicine with an extensive background in early stage biotech companies with successful exits. Anna’s focus is on clinical development and commercialization of novel paradigm shifting diagnostic devices. She has a proven track record of leading the design and development of numerous prospective and retrospective observational clinical trials around the world, the results of which were published in top medical journals and led to successful product commercialization and adoption.
Keith Johnson, PhD
Chief Scientific Officer
As co-chair of the Chromosome-19 Committee of the Human Genome Project, Keith is a well-known leader in the field of human genetics. He has built and led genetic labs for pharmaceutical companies in the U.S. and Europe, and was Executive Director at Novartis and Senior Director of Global R&D at Pfizer. Previously the Professor of Genetics at University of Glasgow, Keith received his PhD in molecular biology at the Imperial College London.
Dr. Loscalzo is the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, Chairman of the Department of Medicine, and Physician-in-Chief at Brigham and Women’s Hospital. He holds two honorary degrees, has authored or co-authored more than 500 scientific publications, and holds 27 patents for his work in the field of medicine. Dr. Loscalzo received his A.B. degree, Ph.D. in biochemistry, and M.D. from the University of Pennsylvania.
Accolades: George W. Thorn Award for Excellence in Teaching at Brigham and Women’s Hospital; Educator of the Year Award in Clinical Medicine from Boston University; The Glaxo Research Award; Election to the American Society for Clinical Investigation, the Association of American Physicians, and the Institute of Medicine of the National Academy of Sciences.
A global business leader and entrepreneur at heart, Alif draws from his scientific background in systems biology, network theory, and engineering at Scipher. Alif has successfully led cross-disciplinary teams in technology and business across Asia, Europe and the Americas – raising over $225 million in venture and private equity capital. Previously with BCI (acquired 2000), Alfa Laval (IPO 2002), and Myriant (acquired 2014), Alif received his MSc degree in Chemical and Genetic Engineering from Lund Institute of Technology, Sweden.
Helia Sanchez, PhD
Helia joined Scipher Medicine as an expert in B cell and mucosal immunology, autoimmunity, and molecular genetics. Her research has led to the discovery of epigenetic therapy for murine lupus and food allergies. She is leading the immunology application of network medicine for both PrismDx and PrismRx. Helia received her Ph.D. in Microbiology, Immunology and Molecular Genetics from the University of Texas Health Science Center at San Antonio.
Nancy Schoenbrunner, PhD
Head of Diagnostic Development
Nancy joins from Roche Molecular Systems where she was Research Director with a proven track record in the medical device, in vitro diagnostic (IVD) and companion diagnostic fields. She headed up the Chemistry and Innovation Technologies department, interfaced closely with the CTO and Business Development and was responsible for the early phase R&D of several portfolios within Roche. Nancy received her Ph. D. in Biophysical Chemistry from the University of Basel.
Chief People Officer
Alison joined Scipher Medicine with 20+ years of Human Resources experience. Prior to joining Scipher, she was the Practice Leader at the Dominis Group where she worked with executives of various stage startup companies to scale their organizations. Her passion is in developing individuals while growing and leading high-performance teams. Alison has also worked in HR and Talent Acquisition for Akamai Technologies, Etex Corporation and Fidelity Investments. Alison holds a BA in Political Science from University of Massachusetts Amherst
Katie brings nine years of business development and marketing experience, mainly focused on early start-ups in the health care space to the Scipher team. She has built and led marketing groups to launch innovative diagnostics tests within psychology, gynecology, and ophthalmology across the US, Spain, and UK. Katie received her BSc in Business Administration from Trinity University in San Antonio, Texas and her MBA from ESADE Business School in Barcelona, Spain.